| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | NEURODERM LTD | 330,000 | 7,326,000 | 1.76% | ||
| 52 | INTERCEPT PHARMACEUTICALS INCORPORATED | 70,000 | 7,606,000 | 1.83% | ||
| 53 | ABBOTT LABS | 200,000 | 7,682,000 | 1.85% | Call | |
| 54 | SEATTLE GENETICS INC | 150,000 | 7,916,000 | 1.91% | ||
| 55 | SPECTRANETICS CORP | 335,000 | 8,208,000 | 1.98% | ||
| 56 | AVEXIS INC COM | 175,000 | 8,353,000 | 2.01% | ||
| 57 | BRISTOL MYERS SQUIBB CO | 150,000 | 8,766,000 | 2.11% | Call | |
| 58 | BOSTON SCIENTIFIC CORP | 450,000 | 9,734,000 | 2.34% | ||
| 59 | CLOVIS ONCOLOGY INC | 220,000 | 9,772,000 | 2.35% | ||
| 60 | ACADIA PHARMACEUTICALS INC COM | 350,000 | 10,094,000 | 2.43% | Call | |
| 61 | NUVASIVE INC | 150,000 | 10,104,000 | 2.43% | ||
| 62 | SAGE THERAPEUTICS INC | 200,000 | 10,212,000 | 2.46% | ||
| 63 | DBV TECHNOLOGIES S A | 325,000 | 11,417,000 | 2.75% | ||
| 64 | CELGENE CORP | 110,000 | 12,733,000 | 3.06% | ||
| 65 | MERCK & CO INC | 225,000 | 13,246,000 | 3.19% | ||
| 66 | ZIMMER BIOMET HLDGS INC | 130,000 | 13,416,000 | 3.23% | ||
| 67 | ALEXION PHARMACEUTIC | 115,000 | 14,070,000 | 3.39% | ||
| 68 | ABBOTT LABS | 400,000 | 15,364,000 | 3.70% | ||
| 69 | SHIRE PLC | 100,000 | 17,038,000 | 4.10% | ||
| 70 | SPDR SER TR | 600,000 | 35,514,000 | 8.55% | Put |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001387131-17-000789, filed 2017.02.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
